CSCI Research Brief

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine. 2019;132(1):56-61. doi:10.1080/00325481.2019.1685298

Long-term (chronic) pain is prevalent in most of the world’s industrial countries. Opioids are commonly used to treat long-term pain, regardless of their severe adverse effects. 

Study Method

An initial group of 131 patients, aged 30 to 65, were recruited from a pain management center to participate in the 9-week study; 97 participants completed the study.  The patients had chronic pain and had been prescribed and taking opioids for at least 12 months. Opioid use, as well as other medications used, was observed and data was recorded at baseline, 4, and 8 weeks. Several parameters were used to measure improvement, including:

  • The Pain Disability Index (PDI-4)
  • The Pittsburgh Sleep Quality Index (PSQI)
  • The Pain Intensity and Interference (PEG)
  • The Patient Health Questionnaire (PHQ-4)

Study Results

The study findings include:

  • Over 50% of those with chronic pain were able to reduce or stop taking opioids within 8 weeks of adding CBD, sourced from hemp, to their pain management regimen.
  • 94% of the study participants reported an increase quality of life as a result of taking CBD for pain.
  • A significant relationship was observed between CBD and the PSQI (i.e., sleep quality) improvement 
  • Improvement was observed in the PHQ (i.e., health questionnaire) and PDI (i.e., pain disability index) but no significant relationship between CBD use and the PDI or PHQ was observed.

The study authors concluded, “CBD could significantly reduce opioid use and improve chronic pain and sleep quality among patients who are currently using opioids for pain management.”

Link to article: https:/doi.org/10.1080/00325481.2019.1685298

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page